Radiofrequency Ablation with an Enhanced-Irrigation Flexible-Tip Catheter versus a Standard-Irrigation Rigid-Tip Catheter.

BACKGROUND: The flexible-tip irrigated ablation catheter Cool Flex™ (St. Jude Medical, St. Paul, MN, USA) was introduced to enhance cooling of the catheter-tissue interface and to conform to endocardial surface with better contact. Little is known about the performance of such catheter design compared to the widely used rigid-tip catheters. METHODS: In a thigh muscle preparation, ablation using the flexible-tip and rigid-tip catheters was performed in seven pigs across a range of ablation settings and catheter orientation. Postprocedure, the thigh muscle was stained with 2,3,5-triphenyltetrazolium-chloride injected into the femoral artery. The muscle was excised, fixed with formalin, and examined grossly. RESULTS: A total of 196 lesions (95 flexible tip, 101 rigid tip) were evaluated. The flexible-tip catheter was associated with enhanced cooling of catheter-tissue interface (31.1 ± 3.3°C vs 36.3 ± 3.7°C, P = 0.0001) in both perpendicular and nonperpendicular catheter orientations. This allowed more energy delivery (37.3 ± 8.9 W vs 33.7 ± 8.1 W, P = 0.004) to targeted tissue and resulted in larger lesions (median 194.7 [interquartile range: 113.1-333.8] mm(3) vs 170.9 [88.7-261.6] mm(3) , P = 0.03) than the rigid-tip catheter with larger maximum diameter (11.1 ± 2.6 mm vs 10.3 ± 2.1 mm, P = 0.03) and larger diameter at tissue surface (10.3 ± 2.4 mm vs 9.6 ± 1.7 mm, P = 0.01). Catheter orientation during ablation affected the efficiency of rigid-tip but not the flexible-tip catheter. The use of the flexible-tip catheter was associated with significantly less char formation on tissue (none vs 5.1% with rigid tip, P = 0.009). CONCLUSION: The Cool Flex™ catheter performed better than a rigid-tip catheter with enhanced cooling, larger ablation lesions, and no charring of targeted tissue.

Motion-activated prevention of clogging and maintenance of patency of indwelling chest tubes.

OBJECTIVES: We designed a device that applies motion-activated energy (vibration) to prevent chest-tube clogging and maintain tube patency. We evaluated the efficacy of this device in vitro and in vivo. METHODS: The motion-activated system (MAS) device assembly comprises a direct current motor with an eccentric mass (3.2 g, centroid radius of 4.53 mm) affixed to its motor shaft. The device was tested in vitro using a model of an obstructed chest tube, with clots of bovine blood and human thrombin. The in vivo study (in nine healthy pigs, 46.0 ± 3.3 kg) involved a bilateral minithoracotomy and placement of 32-Fr chest tubes (with and without the device). Whole autologous blood (120 ml) was injected every 15 min into the right and left chest each over 120 min total. RESULTS: Chest-tube drainage over these 2 h using the MAS was significantly higher than that without the device (369 ± 113 ml vs 209 ± 115 ml; P = 0.027). CONCLUSIONS: Our results suggest that the motion-activation of the chest tubes may be an effective tool to maintain chest tubes patent. Further optimization of this technology is required to obtain more consistent prevention of clot deposition within or outside the chest tubes.